Are You Having Candid Conversations About Your Drug Spend and Profitability?

Asking key questions can help identify new opportunities to drive revenue.

By McKesson Health Systems Editorial Team

Date

June 21, 2024

Read time: 2 minutes

By: McKesson Health Systems Editorial Team

infographic

As new tools and processes for integrating and aligning medication utilization throughout the health system continue to emerge, the business of pharmacy is poised to add clinical and financial value across the entire continuum of care. Still, health system leaders must know which questions to ask about drug spend and profitability to better position the health system pharmacy as a revenue driver versus a cost center. Not only that, but exploring opportunities in outpatient pharmacy, specialty pharmacy, and other areas may further support financial integrity.

Download our eBook, Maximizing Essential Pharmacy Operations to Achieve More, to learn more about critical strategies and considerations for maximizing your health system pharmacy operations to strengthen financial viability, generate revenue, and improve patient outcomes.

Subscribe Now

To learn how McKesson can help health systems achieve more, sign up to have the Prescribed Perspectives newsletter delivered directly to your inbox.

Brittany Ulrich, PharmD, CSP, BCBBS, examines how limited distribution drugs and payer requirements push specialty prescriptions outside the organization, eroding visibility into patient outcomes, and how Biologics by McKesson helps health systems expect more when it comes to maintaining care continuity.

Aerial view of a large warehouse complex with loading docks, trucks and intersecting roads.

Case Study: How McKesson’s Winter-Storm Playbook Kept Specialty Drugs Moving

Expect more for the business of pharmacy with a pressure-tested, multi-layered business continuity strategy.

Researcher in a laboratory looks through shelving lined with containers and supplies.

What You Should Know About the CMS Proposed 340B Payment Change

Dr. Andrew Wilson, B.S., Pharm.D., FASHP, reflects on the proposed CY 2027 OPPS rule for several outpatient drugs purchased through the 340B program, and the next phase of specialty drug margin management for the business of pharmacy.

Open laptop beside a stack of tabbed documents in a binder on a desk, with a softly blurred office background.

Top Prescribed Perspectives Reads for August

The top three Prescribed Perspectives articles most read by health systems in August.

Business professionals greet with a handshake in a modern office while colleagues stand nearby during a networking conversation.

Upcoming Event: inSPire 2026

Connect with McKesson at inSPire to help shape the future of specialty pharmacy

Healthcare professional and colleague review information on a tablet in a clinical setting.

Where Does Your Health System Fall on the Specialty and Infusion Growth Journey?

With our assessment, benchmark your progress across the specialty and infusion journey to achieve more for the business of pharmacy.

Are You Having Candid Conversations About Your Drug Spend and Profitability?

Related Stories

Related Tags